UBS analyst Trung Huynh sees positive trial results supporting continued uptake of GLP-1s. UBS's Eliana Merle defends Madrigal, highlighting Rezdiffra's advantages in the NASH market, with a Buy rating and $411 price target.

Hanesbrands' board sees the Champion transaction as a value maximizer, positioning the company for long-term success by accelerating debt reduction and promoting growth and cash flow through a focused strategy on its leading innerwear brands and supply chain optimization.

McKesson's statutory earnings may not reflect its true productivity due to a large unusual item. Its real earnings power could be less than its statutory profit. Investors should understand the risks, including the identified warning sign with McKesson, before investing.